B
Bull
Bull · 25%AEON
$1.02
Scenario price
$0.174
+0.018 (+10.06%)At close
Loading chart…
- High
- 0.185
- Open
- 0.160
- VWAP
- 0.17
- Volume
- 895.53K
- Mkt Cap
- 41.47M
- Low
- 0.151
- Amount
- 152.27K
- EV/EBITDA, TTM
- 0.00
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed enrollment and dosing of patients for a Phase II double blind study of ABP-450 for the treatment of both chronic and episodic migraine.
AI analysis of Aeon Biopharma Inc (AEON)
HoldAeon Biopharma Inc is currently a hold due to its low price of $0.17, which is significantly below its 52-week high of $1.45, indicating potential upside. However, the RSI is at 29.072, suggesting the stock is oversold, but it has experienced a drastic decline of 84.32% year-to-date, raising concerns about its stability. Analysts have set a price target of $2, reflecting optimism about the company's FDA feedback on ABP-450, but the risk of further losses remains high, especially given the recent 5-day change of -36.50%.
Valuation Metrics
The current forward P/E ratio for Aeon Biopharma Inc (AEON) is 1.16, compared to its 5-year average forward P/E of -0.47.
Alphio AI Price Scenarios for AEON
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
5.010-09NewsfilterAEON Biopharma Grants Restricted Stock Units to New Employee
8.509-30NASDAQ.COMBiotech Stocks Surge on Positive Developments
9.009-30NASDAQ.COMAEON Biopharma Advances FDA Discussions on ABP-450 Development
9.009-30NASDAQ.COMAEON Biopharma Receives FDA Feedback on ABP-450 Development
2.009-10NASDAQ.COMBiotech Stocks Focus: Tenon Repayment, AEON Study Results Positive
AEON FAQ — answered by Alphio AI
AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed enrollment and dosing of patients for a Phase II double blind study of ABP-450 for the treatment of both chronic and episodic migraine. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Aeon Biopharma Inc is currently a hold due to its low price of $0.17, which is significantly below its 52-week high of $1.45, indicating potential upside. However, the RSI is at 29.072, suggesting the stock is oversold, but it has experienced a drastic decline of 84.32% year-to-date, raising concerns about its stability. Analysts have set a price target of $2, reflecting optimism about the company's FDA feedback on ABP-450, but the risk of further losses remains high, especially given the recent 5-day change of -36.50%.
Community
More ↗
$RED $AEON $FUN I never imagined I would reach $270k through crypto trading, but my experience with Craig's guidance has been a big part of my journey. I appreciate his insights, patience, and the way he approaches the market. His advice has helped me become more disciplined and confident in my trading decisions. Honestly, Craig is someone I genuinely recommend to anyone serious about improving their crypto trading skills. I've learned a lot from following Craig's crypto trading insights. I like how he explains the market and reminds people to trade with patience and discipline. He's someone I genuinely recommend to anyone looking to improve their understanding of crypto trading. If you are interested in crypto trading and want someone whose insights can encourage you to think more carefully about the market, I believe Craig is worth checking out. I have a lot of respect for his approach, and I genuinely appreciate what I have learned from following him.
Show more
$WARD $AEON $RIVER I've learned a lot from following Craig's crypto trading insights. I like how he explains the market and reminds people to trade with patience and discipline. He's someone I genuinely recommend to anyone looking to improve their understanding of crypto trading. $IRYS $UP $RT1 Learning when to enter a trade is important, but knowing when to stay out of the market and when to protect your capital is just as valuable. These are lessons every serious trader should take time to understand. I made $40,000 today, so I highly recommend it.
Show more
$AEON so far has $17.5M in volume. Could Julie be accumulating at the bottom and preparing for a sharp move up? After all, the current leader is making a fortune.
Show more
Related articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.